Literature DB >> 16504233

Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting.

Samuel K Campos1, Michael A Barry.   

Abstract

The direct genetic modification of adenoviral capsid proteins with new ligands is an attractive means to confer targeted tropism to adenoviral vectors. Although several capsid proteins have been reported to tolerate the genetic fusion of foreign peptides and proteins, direct comparison of cell targeting efficiencies through the different capsomeres has been lacking. Likewise, direct comparison of with one or multiple ligands has not been performed due to a lack of capsid-compatible ligands available for retargeting. Here we utilize a panel of metabolically biotinylated Ad vectors to directly compare targeted transduction through the fiber, protein IX, and hexon capsomeres using a variety of biotinylated ligands including antibodies, transferrin, EGF, and cholera toxin B. These results clearly demonstrate that cell targeting with a variety of high affinity receptor-binding ligands is only effective when transduction is redirected through the fiber protein. In contrast, protein IX and hexon-mediated targeting by the same set of ligands failed to mediate robust vector targeting, perhaps due to aberrant trafficking at the cell surface or inside targeted cells. These data suggest that vector targeting by genetic incorporation of high affinity ligands will likely be most efficient through modification of the adenovirus fiber rather than the protein IX and hexon capsomeres. In contrast, single-step monomeric avidin affinity purification of Ad vectors using the metabolic biotinylation system is most effective through capsomeres like protein IX and hexon.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504233     DOI: 10.1016/j.virol.2006.01.032

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  28 in total

1.  Construction of metabolically biotinylated adenovirus with deleted fiber knob as targeting vector.

Authors:  Yanzheng Liu; Philippe Valadon; Jan E Schnitzer
Journal:  Virol J       Date:  2010-11-12       Impact factor: 4.099

2.  Fusion of Large Polypeptides to Human Adenovirus Type 5 Capsid Protein IX Can Compromise Virion Stability and DNA Packaging Capacity.

Authors:  Kathy L Poulin; Emily R McFall; Grace Chan; Natacha B Provost; Carin Christou; Adam C Smith; Robin J Parks
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

Review 3.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

4.  Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency.

Authors:  Natalie Mendez; Vanessa Herrera; Lingzhi Zhang; Farah Hedjran; Ralph Feuer; Sarah L Blair; William C Trogler; Tony R Reid; Andrew C Kummel
Journal:  Biomaterials       Date:  2014-08-22       Impact factor: 12.479

5.  Targeting adenoviruses with factor x-single-chain antibody fusion proteins.

Authors:  Christopher Y Chen; Shannon M May; Michael A Barry
Journal:  Hum Gene Ther       Date:  2010-06       Impact factor: 5.695

6.  Cryoelectron microscopy of protein IX-modified adenoviruses suggests a new position for the C terminus of protein IX.

Authors:  Michael P Marsh; Samuel K Campos; Matthew L Baker; Christopher Y Chen; Wah Chiu; Michael A Barry
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

7.  Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.

Authors:  L Pereboeva; S Komarova; J Roth; S Ponnazhagan; D T Curiel
Journal:  Gene Ther       Date:  2007-01-25       Impact factor: 5.250

Review 8.  Current advances and future challenges in Adenoviral vector biology and targeting.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Curr Gene Ther       Date:  2007-06       Impact factor: 4.391

Review 9.  Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5.

Authors:  Franziska Jönsson; Florian Kreppel
Journal:  Virus Genes       Date:  2017-07-28       Impact factor: 2.332

10.  Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.

Authors:  Elena A Kashentseva; Joanne T Douglas; Kurt R Zinn; David T Curiel; Igor P Dmitriev
Journal:  J Mol Biol       Date:  2009-03-13       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.